Close

BioMarin Pharma's (BMRN) BMN 270 Granted Orphan Drug Designation by European Commission

March 24, 2016 8:33 AM EDT Send to a Friend
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that BMN 270, an investigational gene therapy for the treatment of hemophilia A, has ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login